V600EBRAF promotes invasiveness of thyroid cancer cells by decreasing E-cadherin expression through a Snail-dependent mechanism

Cancer Letters

Volumn 335, Issue 1, 2013, Pages 232-241

  Baquero, Pablo ^a   Sánchez Hernández, Irene ^a   Jiménez Mora, Eva ^a   Orgaz, Jose L ^b   Jiménez, Benilde ^b   Chiloeches, Antonio ^a  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

Author keywords

BRAF; E cadherin; EMT; Invasion; Snail; Thyroid cancer

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; MITOGEN ACTIVATED PROTEIN KINASE; N [3 (5 CHLORO 1H PYRROLO[2,3 B]PYRIDINE 3 CARBONYL) 2,4 DIFLUOROPHENYL]PROPANESULFONAMIDE; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR SNAIL; UVOMORULIN;

ARTICLE; BRAF GENE; CANCER CELL; CANCER GROWTH; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYROID CANCER; UPREGULATION; WILD TYPE;

BUTADIENES; CADHERINS; CARCINOMA; CELL LINE, TUMOR; CELL MOVEMENT; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; INDOLES; MAP KINASE KINASE KINASES; MUTATION, MISSENSE; NEOPLASM INVASIVENESS; NITRILES; PROTO-ONCOGENE PROTEINS B-RAF; RNA, SMALL INTERFERING; SULFONAMIDES; THYROID NEOPLASMS; TRANSCRIPTION FACTORS;

GASTROPODA;

EID: 84878437294     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.02.033     Document Type: Article

References (50)

1. Kazaure H.S., Roman S.A., Sosa J.A. Aggressive variants of papillary thyroid cancer: incidence, characteristics and predictors of survival among 43,738 patients. Ann. Surg. Oncol. 2012, 19:1874-1880.
2. Nagaiah G., Hossain A., Mooney C.J., Parmentier J., Remick S.C. Anaplastic thyroid cancer: a review of epidemiology, pathogenesis, and treatment. J. Oncol. 2011, 542358.
3. Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr. Rev. 2007, 28:742-762.
4. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C., Shipley J., Hargrave D., Pritchard-Jones K., Maitland N., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A., Nicholson A., Ho J.W., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
5. Karasarides M., Chiloeches A., Hayward R., Niculescu-Duvaz D., Scanlon I., Friedlos F., Ogilvie L., Hedley D., Martin J., Marshall C.J., Springer C.J., Marais R. B-RAF is a therapeutic target in melanoma. Oncogene 2004, 23:6292-6298.
6. Riesco-Eizaguirre G., Rodriguez I., De la Vieja A., Costamagna E., Carrasco N., Nistal M., Santisteban P. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer. Cancer Res. 2009, 69:8317-8325.
7. Knauf J.A., Ma X., Smith E.P., Zhang L., Mitsutake N., Liao X.H., Refetoff S., Nikiforov Y.E., Fagin J.A. Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res. 2005, 65:4238-4245.
8. Nucera C., Nehs M.A., Nagarkatti S.S., Sadow P.M., Mekel M., Fischer A.H., Lin P.S., Bollag G.E., Lawler J., Hodin R.A., Parangi S. Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer. Oncologist 2011, 16:296-309.
9. Knauf J.A., Sartor M.A., Medvedovic M., Lundsmith E., Ryder M., Salzano M., Nikiforov Y.E., Giordano T.J., Ghossein R.A., Fagin J.A. Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFbeta signaling. Oncogene 2011, 30:3153-3162.
10. Thiery J.P., Acloque H., Huang R.Y., Nieto M.A. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139:871-890.
11. Guarino M. Epithelial-mesenchymal transition and tumour invasion. Int. J. Biochem. Cell. Biol. 2007, 39:2153-2160.
12. Perl A.K., Wilgenbus P., Dahl U., Semb H., Christofori G. A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature 1998, 392:190-193.
13. Frixen U.H., Behrens J., Sachs M., Eberle G., Voss B., Warda A., Lochner D., Birchmeier W. E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J. Cell. Biol. 1991, 113:173-185.
14. Vleminckx K., Vakaet L., Mareel M., Fiers W., van Roy F. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell 1991, 66:107-119.
15. Brabant G., Hoang-Vu C., Cetin Y., Dralle H., Scheumann G., Molne J., Hansson G., Jansson S., Ericson L.E., Nilsson M. E-cadherin: a differentiation marker in thyroid malignancies. Cancer Res. 1993, 53:4987-4993.
16. Serini G., Trusolino L., Saggiorato E., Cremona O., De Rossi M., Angeli A., Orlandi F., Marchisio P.C. Changes in integrin and E-cadherin expression in neoplastic versus normal thyroid tissue. J. Natl. Cancer Inst. 1996, 88:442-449.
17. Batlle E., Sancho E., Franci C., Dominguez D., Monfar M., Baulida J., Garcia De Herreros A. The transcription factor Snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat. Cell. Biol. 2000, 2:84-89.
18. Bolos V., Peinado H., Perez-Moreno M.A., Fraga M.F., Esteller M., Cano A. The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors. J. Cell. Sci. 2003, 116:499-511.
19. Cano A., Perez-Moreno M.A., Rodrigo I., Locascio A., Blanco M.J., del Barrio M.G., Portillo F., Nieto M.A. The transcription factor Snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat. Cell. Biol. 2000, 2:76-83.
20. Sugimachi K., Tanaka S., Kameyama T., Taguchi K., Aishima S., Shimada M., Tsuneyoshi M. Transcriptional repressor snail and progression of human hepatocellular carcinoma. Clin. Cancer Res. 2003, 9:2657-2664.
21. Perez-Mancera P.A., Perez-Caro M., Gonzalez-Herrero I., Flores T., Orfao A., de Herreros A.G., Gutierrez-Adan A., Pintado B., Sagrera A., Sanchez-Martin M., Sanchez-Garcia I. Cancer development induced by graded expression of Snail in mice. Hum. Mol. Genet. 2005, 14:3449-3461.
22. Peinado H., Olmeda D., Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?. Nat. Rev. Cancer 2007, 7:415-428.
23. Christofori G. New signals from the invasive front. Nature 2006, 441:444-450.
24. Massoumi R., Kuphal S., Hellerbrand C., Haas B., Wild P., Spruss T., Pfeifer A., Fassler R., Bosserhoff A.K. Down-regulation of CYLD expression by Snail promotes tumor progression in malignant melanoma. J. Exp. Med. 2009, 206:221-232.
25. Hardy R.G., Vicente-Duenas C., Gonzalez-Herrero I., Anderson C., Flores T., Hughes S., Tselepis C., Ross J.A., Sanchez-Garcia I. Snail family transcription factors are implicated in thyroid carcinogenesis. Am. J. Pathol. 2007, 171:1037-1046.
26. Tsai J., Lee J.T., Wang W., Zhang J., Cho H., Mamo S., Bremer R., Gillette S., Kong J., Haass N.K., Sproesser K., Li L., Smalley K.S., Fong D., Zhu Y.L., Marimuthu A., Nguyen H., Lam B., Liu J., Cheung I., Rice J., Suzuki Y., Luu C., Settachatgul C., Shellooe R., Cantwell J., Kim S.H., Schlessinger J., Zhang K.Y., West B.L., Powell B., Habets G., Zhang C., Ibrahim P.N., Hirth P., Artis D.R., Herlyn M., Bollag G. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc. Natl. Acad. Sci. USA 2008, 105:3041-3046.
27. Xing J., Liu R., Xing M., Trink B. The BRAFT1799A mutation confers sensitivity of thyroid cancer cells to the BRAFV600E inhibitor PLX4032 (RG7204). Biochem. Biophys. Res. Commun. 2011, 404:958-962.
28. Chakravarty D., Santos E., Ryder M., Knauf J.A., Liao X.H., West B.L., Bollag G., Kolesnick R., Thin T.H., Rosen N., Zanzonico P., Larson S.M., Refetoff S., Ghossein R., Fagin J.A. Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. J. Clin. Invest. 2011, 121:4700-4711.
29. Chapman P.B., Hauschild A., Robert C., Haanen J.B., Ascierto P., Larkin J., Dummer R., Garbe C., Testori A., Maio M., Hogg D., Lorigan P., Lebbe C., Jouary T., Schadendorf D., Ribas A., O'Day S.J., Sosman J.A., Kirkwood J.M., Eggermont A.M., Dreno B., Nolop K., Li J., Nelson B., Hou J., Lee R.J., Flaherty K.T., McArthur G.A. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. New Engl. J. Med. 2011, 364:2507-2516.
30. Denoyelle C., Abou-Rjaily G., Bezrookove V., Verhaegen M., Johnson T.M., Fullen D.R., Pointer J.N., Gruber S.B., Su L.D., Nikiforov M.A., Kaufman R.J., Bastian B.C., Soengas M.S. Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway. Nat. Cell. Biol. 2006, 8:1053-1063.
31. Schweppe R.E., Klopper J.P., Korch C., Pugazhenthi U., Benezra M., Knauf J.A., Fagin J.A., Marlow L.A., Copland J.A., Smallridge R.C., Haugen B.R. Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J. Clin. Endocrinol. Metab. 2008, 93:4331-4341.
32. Hatzivassiliou G., Song K., Yen I., Brandhuber B.J., Anderson D.J., Alvarado R., Ludlam M.J., Stokoe D., Gloor S.L., Vigers G., Morales T., Aliagas I., Liu B., Sideris S., Hoeflich K.P., Jaiswal B.S., Seshagiri S., Koeppen H., Belvin M., Friedman L.S., Malek S. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010, 464:431-435.
33. Poulikakos P.I., Persaud Y., Janakiraman M., Kong X., Ng C., Moriceau G., Shi H., Atefi M., Titz B., Gabay M.T., Salton M., Dahlman K.B., Tadi M., Wargo J.A., Flaherty K.T., Kelley M.C., Misteli T., Chapman P.B., Sosman J.A., Graeber T.G., Ribas A., Lo R.S., Rosen N., Solit D.B. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2010, 480:387-390.
34. Salerno P., De Falco V., Tamburrino A., Nappi T.C., Vecchio G., Schweppe R.E., Bollag G., Santoro M., Salvatore G. Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells. J. Clin. Endocrinol. Metab. 2010, 95:450-455.
35. Nucera C., Porrello A., Antonello Z.A., Mekel M., Nehs M.A., Giordano T.J., Gerald D., Benjamin L.E., Priolo C., Puxeddu E., Finn S., Jarzab B., Hodin R.A., Pontecorvi A., Nose V., Lawler J., Parangi S. B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression. Proc. Natl. Acad. Sci. USA 2010, 107:10649-10654.
36. Peinado H., Portillo F., Cano A. Transcriptional regulation of cadherins during development and carcinogenesis. Int. J. Dev. Biol. 2004, 48:365-375.
37. Vasko V., Espinosa A.V., Scouten W., He H., Auer H., Liyanarachchi S., Larin A., Savchenko V., Francis G.L., de la Chapelle A., Saji M., Ringel M.D. Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion. Proc. Natl. Acad. Sci. USA 2007, 104:2803-2808.
38. Liu Z., Kakudo K., Bai Y., Li Y., Ozaki T., Miyauchi A., Taniguchi E., Mori I. Loss of cellular polarity/cohesiveness in the invasive front of papillary thyroid carcinoma, a novel predictor for lymph node metastasis; possible morphological indicator of epithelial mesenchymal transition. J. Clin. Pathol. 2011, 64:325-329.
39. Wiseman S.M., Griffith O.L., Deen S., Rajput A., Masoudi H., Gilks B., Goldstein L., Gown A., Jones S.J. Identification of molecular markers altered during transformation of differentiated into anaplastic thyroid carcinoma. Arch. Surg. 2007, 142:717-727. discussion 727-29.
40. Wiseman S.M., Masoudi H., Niblock P., Turbin D., Rajput A., Hay J., Bugis S., Filipenko D., Huntsman D., Gilks B. Anaplastic thyroid carcinoma: expression profile of targets for therapy offers new insights for disease treatment. Ann. Surg. Oncol. 2007, 14:719-729.
41. Montero-Conde C., Martin-Campos J.M., Lerma E., Gimenez G., Martinez-Guitarte J.L., Combalia N., Montaner D., Matias-Guiu X., Dopazo J., de Leiva A., Robledo M., Mauricio D. Molecular profiling related to poor prognosis in thyroid carcinoma. Combining gene expression data and biological information. Oncogene 2008, 27:1554-1561.
42. Zhu L.F., Hu Y., Yang C.C., Xu X.H., Ning T.Y., Wang Z.L., Ye J.H., Liu L.K. Snail overexpression induces an epithelial to mesenchymal transition and cancer stem cell-like properties in SCC9 cells. Lab. Invest. 2012, 92:744-752.
43. Lin K., Baritaki S., Militello L., Malaponte G., Bevelacqua Y., Bonavida B. The role of B-RAF mutations in melanoma and the induction of EMT via dysregulation of the NF-kappaB/Snail/RKIP/PTEN circuit. Genes Cancer 2010, 1:409-420.
44. Palona I., Namba H., Mitsutake N., Starenki D., Podtcheko A., Sedliarou I., Ohtsuru A., Saenko V., Nagayama Y., Umezawa K., Yamashita S. BRAFV600E promotes invasiveness of thyroid cancer cells through nuclear factor kappaB activation. Endocrinology 2006, 147:5699-5707.
45. Pacifico F., Leonardi A. Role of NF-kappaB in thyroid cancer. Mol. Cell. Endocrinol. 2010, 321:29-35.
46. Zhou B.P., Deng J., Xia W., Xu J., Li Y.M., Gunduz M., Hung M.C. Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat. Cell. Biol. 2004, 6:931-940.
47. Huber M.A., Kraut N., Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr. Opin. Cell. Biol. 2005, 17:548-558.
48. Hu S., Liu D., Tufano R.P., Carson K.A., Rosenbaum E., Cohen Y., Holt E.H., Kiseljak-Vassiliades K., Rhoden K.J., Tolaney S., Condouris S., Tallini G., Westra W.H., Umbricht C.B., Zeiger M.A., Califano J.A., Vasko V., Xing M. Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer. Int. J. Cancer 2006, 119:2322-2329.
49. Smith J.A., Fan C.Y., Zou C., Bodenner D., Kokoska M.S. Methylation status of genes in papillary thyroid carcinoma. Arch. Otolaryngol. Head Neck Surg. 2007, 133:1006-1011.
50. Liu D., Hu S., Hou P., Jiang D., Condouris S., Xing M. Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant. Clin. Cancer Res. 2007, 13:1341-1349.